Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 19;8(2):e002165. doi: 10.1136/rmdopen-2021-002165

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Proportion of patients achieving ASAS40 and ASDAS major improvement, ASDAS <2.1 and BASDAI50 responses, for 116 weeks of IXE Q4W treatment for (A, C, E, G) biological DMARD (bDMARD)-naïve patients and (B, D, F, H) TNFi-experienced patients. Missing data among the IXE Q4W treated patients were imputed using NRI. The study was not designed to allow comparison between bDMARD-naïve patients with r-axSpA and bDMARD-naïve patients with nr-axSpA. Data are presented as the proportion (%) of patients, both NRI (black) and observed (grey) values. ASAS40, 40% improvement in Assessment of Spondyloarthritis International Society criteria; ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, axial spondyloarthritis; BASDAI50, 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index; DMARD, disease-modifying antirheumatic drug; IXE, ixekizumab; nr-axSpA, non-radiographic axSpA; r-axSpA, radiographic axSpA; TNFi, tumour necrosis factor inhibitor.